Neurofibroma differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) |
||
Line 58: | Line 58: | ||
|Positive for: | |Positive for: | ||
* S100 | * S100 | ||
* Sox10 | |||
* Neurofilament (and Bielshowsky) | |||
* GFAP | * GFAP | ||
* CD34 | * CD34 | ||
* Factor XIIIa | |||
* Calretinin (focal) | |||
| | | | ||
| | | | ||
Line 79: | Line 83: | ||
| | | | ||
| | | | ||
* Encapsulated | |||
* Biphasic (cellular Antoni A & hypocellular Antoni B) | |||
* Hypercellularity | |||
* Palisading | |||
* Verocay bodies | |||
|Positive for: | |||
* S-100 | |||
* Sox10 | |||
* CD34 | |||
* Neurofilament (and Bielshowsky) | |||
* Factor XIIIa (focal) | |||
* Calretinin | |||
* GFAP | |||
| | | | ||
| | | | ||
* NF-2 associated | |||
| | | | ||
| | | | ||
| | | | ||
* Nerve often identifiable | |||
* Eccentric to nerve, axons generally absent within lesion | |||
* Occasionally cystic | |||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |'''Palisaded encapsulated neuroma''' | | style="background:#DCDCDC;" align="center" + |'''Palisaded encapsulated neuroma''' |
Revision as of 19:51, 29 March 2019
Neurofibroma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Neurofibroma differential diagnosis On the Web |
American Roentgen Ray Society Images of Neurofibroma differential diagnosis |
Risk calculators and risk factors for Neurofibroma differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2] Shanshan Cen, M.D. [3]
Overview
Neurofibroma must be differentiated from schwannoma, dermatofibrosarcoma protuberans (DFSP), ganglioneuroma, and melanocytic nevus.
Differential Diagnosis
Neurofibroma must be differentiated from:[1]
- Schwannoma
- Dermatofibrosarcoma protuberans (DFSP)
- Ganglioneuroma
- Melanocytic nevus
- Myxoid liposarcoma
- Solitary circumscribed neuroma (palisaded encapsulated neuroma)
- Traumatic neuroma
- Neurotized nevus
- Superficial angiomyxoma
- Nerve sheath myxoma
- Malignant peripheral nerve sheath tumor (MPNST): has marked atypia and increased mitotic activity, may have necrosis
- Spindle cell lipoma
- Leiomyoma: has cigar-shaped nuclei, S100 negative, positive for smooth muscle actin and desmin
- Inflammatory myofibroblastic tumor: reactive spindle cells in inflammatory background
Disease entity | Etiology (Genetic or other) | Histopathological findings | Immunohistochemical staining | Benign/Malignant | Risk factors | Common site of involvement | Clinical manifestations | Other associated features |
---|---|---|---|---|---|---|---|---|
Neurofibroma |
Neurofibroma with degenerative atypia ("ancient change") has following microscopic features:
|
Positive for:
|
|
|
| |||
Schwannoma |
|
Positive for:
|
|
| ||||
Palisaded encapsulated neuroma | ||||||||
Traumatic neuroma | ||||||||
Neurotized Melanocytic Nevus | ||||||||
Cutaneous Myxoma (Superficial angiomyxoma) | ||||||||
Nerve sheath myxoma | ||||||||
Malignant peripheral nerve sheath tumor | ||||||||
Dermatofibrosarcoma protuberans (DFSP) | ||||||||
Spindle cell lipoma |
References
- ↑ Neurofibroma. Libre Pathology 2015. http://librepathology.org/wiki/index.php/Neurofibroma#cite_note-pmid15486243-2 Accessed on November 17, 2015